Global Pediatric Congenital Athymia Treatment Market, By Therapy Type (Regenerative Advanced Medicine Therapy, Hormonal Replacement Therapy), Treatment (Medication, Surgery, Palatoplasty), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Pediatric congenital athymia treatment Market Analysis and Size
The pediatric congenital athymia treatment market is projected to witness major growth during the forecast period. The vulnerable Di-George syndrome pediatric population with the beginning of medicines for the treatment of serious diseases such as CNS and cardiovascular diseases and increase in the pace of R&D initiatives are some major market drivers for the pediatric congenital athymia treatment market.
Data Bridge Market Research analyses a growth rate in the pediatric congenital athymia treatment market in the forecast period 2023-2030. The expected CAGR of pediatric congenital athymia treatment market is tend to be around 4% in the mentioned forecast period. The market was valued at USD 100 million in 2022, and it would grow upto USD 136.86 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Pediatric congenital athymia treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Therapy Type (Regenerative Advanced Medicine Therapy, Hormonal Replacement Therapy), Treatment (Medication, Surgery, Palatoplasty), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Johnson & Johnson Private Limited (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Bausch Health Companies Inc. (Canada), Biora Therapeutics, Inc (U.S.), Boehringer Ingelheim International Gmbh (Germany), Amgen Inc. (U.S.), Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Sumitomo Pharma Co., Ltd (Japan), CELGENE CORPORATION (U.S.), CELLECTAR BIOSCIENCES, INC (U.S.), eFFECTOR Therapeutics, Inc (U.S.), IMV Inc (Canada), Karyopharm (U.S.), Novartis AG (Switzerland)
|
|
Market Opportunities
|
|
Market Definition
Pediatric congenital athymia is a rare type of condition that is associated with complete anomaly of Di-George, charging syndrome and deficiency of FOXN1. Children who are suffering from this condition are born without a thymus, leading to extreme immunodeficiency because of the inability to produce normally functioning T cells, that protect against infection and control important immune system processes. Multiple genetic abnormalities, congenital syndromes, and environmental factors that are being associated, and the care of these infants is complex.
Global Pediatric congenital athymia treatment Market Dynamics
Drivers
- Rising Awareness For Disease Treatment
Growing awareness among patients and numerous healthcare professionals for treating different types of congenital syndromes and more and more usage of combination therapy are the major factors projected to boost the demand for pediatric congenital athymia market during the forecast period of 2023-2030.
- Increased Clinical Studies and Government Initiatives
The market growth is fuelled by an increase in the number of R&D activities. This will provide beneficial opportunities for the pediatric drugs market growth. The presence of several measures such as the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) is driving big businesses to improve their R&D investments in pediatric drug research. Along with this, increasing drug approvals and launches will further boost the market’s growth rate.
Opportunities
- Increasing Demand for Retail Pharmacies
Increase in the number of pediatric congenital athymia therapeutics being delivered through retail pharmacies and also increase in the number of retail pharmacies in highly developed countries create much opportunities for the market growth. In addition to this, patients opt for retail pharmacies for purchasing drugs, due to its easy accessibility .
- Increasing Incidence of Chronic Disorders
The increasing prevalence of chronic disorders is estimated to enhance the market's growth. Chronic disorders such as asthma, birth defects, anorexia, growth deficiencies, diabetes, juvenile diabetes, cancer in children, and attention deficit hyperactivity among others is the major factor enhancing the demand of pediatric drugs, influencing the market dynamics.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained healthcare professionals who are unaware of the knowledge of the treatment methods for this disease could reduce the growth of the global pediatric congenital athymia treatment market during the forecast period.
- Side Effects
The side effects associated with pediatric congenital athymia drugs, including headache, anxiety, and lack of awareness among people, will act as restrain and further hinder the market's growth rate during the forecast period.
This pediatric congenital athymia treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pediatric congenital athymia treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development:
- In October 2021, the U.S. FDA announced the approval of rethymic used to treat paediatric patients suffering from congenital athymia. Rethymic is the first thymus tissue product approved in the U.S.
Global Pediatric Congenital Athymia Treatment Scope
The pediatric congenital athymia treatment market is segmented on the basis of therapy type, treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Therapy Type
- Regenerative Advanced Medicine Therapy
- Hormonal Replacement Therapy
Treatment
- Medication
- Surgery
- Palatoplasty
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Pediatric Congenital Athymia Treatment Market Regional Analysis/Insights
The pediatric congenital athymia treatment market is analyzed and market size insights and trends are provided by therapy type, treatment, distribution channel and end-user as referenced above.
The major countries covered in the pediatric congenital athymia treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the presence of advanced technologies, healthcare expenditure and skilled professionals.
Asia Pacific dominates the market due to lack of awareness among such rare disease.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Pediatric Congenital Athymia Treatment Market Share Analysis
The pediatric congenital athymia treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to pediatric congenital athymia treatment market.
Key players operating in the pediatric congenital athymia treatment market include:
- Johnson & Johnson Private Limited (U.S.)
- Abbott (U.S.)
- AbbVie Inc. (U.S.)
- Bausch Health Companies Inc. (Canada)
- Biora Therapeutics, Inc (U.S.)
- Boehringer Ingelheim International Gmbh (Germany)
- Amgen Inc. (U.S.)
- Pfizer Inc (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Mylan N.V. (U.S.)
- Sumitomo Pharma Co., Ltd (Japan)
- CELGENE CORPORATION (U.S.)
- CELLECTAR BIOSCIENCES, INC (U.S.)
- eFFECTOR Therapeutics, Inc (U.S.)
- IMV Inc (Canada)
- Karyopharm (U.S.)
- Novartis AG (Switzerland)
SKU-